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Abstract: Actinic keratoses are encountered by physicians worldwide on a daily basis. As 
these precancerous lesions can transform to skin carcinomas, it is important to understand 
the many available options to use as treatment. In recent years, new therapeutic options have 
emerged to treat this common condition. These treatments as well as a review of the literature 
of conventional therapies will be discussed.
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General
Actinic keratoses or solar keratoses are among one of the most frequent diagnoses 
among dermatologists worldwide. The prevalence of actinic keratoses in Australia 
is estimated to be approximately 40%.1 The risk of developing actinic keratoses is 
even higher in immunocompromised patients. This public health epidemic is similar 
in the United States where 60% of people over the age of 40 with predisposed risk 
factors such as chronic sun exposure, outdoor occupation, fair skin, light eye color, 
and frequent sunburns have at least one actinic keratosis.2 Moreover, in 2002, it has 
been estimated that more than 8.2 million visits to physicians in the United States 
were related to actinic keratoses.3 The estimated annual cost to treat actinic keratoses 
in the United States alone is approximately $900 million.4
The morphology of actinic keratoses can vary widely. The most common presen-
tation is that of a pink scaly patch or plaque on an erythematous base. Even though 
actinic keratoses typically are a few millimeters in size, they can reach confluent patches 
of a few centimeters in diameter. Some other subtypes of actinic keratoses include: 
pigmented actinic keratoses, which present as hyperpigmented scaly patches; hyper-
keratotic actinic keratoses, which present with a thick scale crust on an erythematous 
base; and lichenoid actinic keratoses, which clinically appear with more erythema 
surrounding the base of the lesion and histologically show a dense band-like inflamma-
tory infiltrate. When actinic keratoses appear on the lip, they are referred to as actinic 
chelitis. They are characteristically found on the lower lip and can be present focally 
or encompass the majority of the lip.
Although these lesions can be found anywhere on the body, they are typically 
located on sun-exposed areas such as the face, neck, and extremities. It is thought the 
irradiation from the sun produces genetic mutations in keratinocytes as well as loss 
of tumor suppressor genes such as p53.5 These changes coupled with suppression of 
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to present antigen to helper TH1 lymphocytes result in the 
development of actinic keratoses.6
It is important for clinicians to recognize and effectively 
treat actinic keratoses given their potential to develop into 
squamous cell carcinomas as well as the belief of some that 
these lesions represent an early squamous cell carcinoma 
in situ. In a study of 169 people performed by the United 
States Department of Veteran Affairs, 65% of squamous 
cell carcinomas occurred from actinic keratoses.7 This was 
further confirmed by Hurwitz et al who found 444 of 459 
(97%) subjects had a contiguous actinic keratosis near the 
site of their squamous cell carcinoma.8 Given the prevalence 
of actinic keratoses and the risk of subsequent develop-
ment to squamous cell carcinoma, this review article will 
discuss the treatment options for physicians to consider 
when treating patients with this common condition. Both 
the number of lesions and the tolerability of the treatment 
need to be considered when choosing the appropriate regi-
men for patients.
Destructive measures
One of the most common forms of treatment for actinic 
keratoses is the use of cryosurgery with liquid nitrogen as 
the cryogen. Liquid nitrogen can be applied either via a cry-
ospray, cryoprobe, or cotton tip. When liquid nitrogen makes 
contact with the skin, the temperature of the treated area is 
lowered to −50°C. The mechanism of action involves direct 
cellular freezing as well as vascular stasis occurring after 
thawing. The duration of the freezing time varies based upon 
the size and thickness of the particular lesion being treated. 
Thicker hyperkeratotic actinic keratoses can require up to 
30 seconds of treatment where thin lesions are destroyed 
with a 5–7 second freeze time. To ensure eradication of the 
actinic keratosis, it is important to achieve a 2–4 mm margin 
of freeze around the target lesion. It has been estimated that 
cure rates of up to 98% occur in individual actinic keratoses 
following cryotherapy.9 While the procedure is performed, 
patients experience mild pain, residual erythema, and crust 
formation. Blistering often develops which can last up to 
3 weeks until the lesion is healed. The most notable long-
term sequele is hypopigmentation, especially in darker com-
plected individuals. A limitation of cryosurgery is the focus 
on discrete lesions and not on subclinical actinic keratoses, 
which occur in wide photodamaged areas. These subclini-
cal lesions will continue to grow to form clinically apparent 
actinic keratoses and subsequent squamous cell carcinomas 
if left untreated.
The use of a curette, with or without electrosurgery, is 
also utilized to treat actinic keratoses. It has been estimated 
that curettage and cryosurgery account for approximately 
78% of all treatments for actinic keratoses in the United 
States.10 The method of curettage is particularly effective 
for the treatment of thicker, hypertrophic actinic keratoses as 
the curette mechanically scrapes away the atypical keratino-
cytes. If hemostasis is required after the procedure or if the 
physician wishes to further destroy the lesion, electrosurgery 
can be performed. In addition to the failure to treat actinic 
keratoses that are not yet clinically present, dyspigmentation, 
scarring, and rarely infection can arise. In the case of large 
hypertrophic, thick actinic keratoses, surgical excision can 
also be considered.
Another treatment modality is the use of medium-depth 
chemical peels with 35% trichloroacetic acid and Jessner’s 
solution. This treatment allows a more widespread area of 
treatment with efficacy rates of up to 75% at 1 month.11 The 
peel is generally well tolerated with desquamation and ery-
thema lasting 10–14 days after the procedure. One limitation 
is that thick, hypertrophic actinic keratoses generally do not 
respond well.
The use of ablative lasers such as the carbon dioxide 
and erbium:yttrium-aluminum-garnet (erbium:YAG) laser 
have been shown to be effective in the treatment of actinic 
keratoses. Trimas et al found the carbon dioxide laser to be 
a safe and effective treatment in 14 patients treated with 
extensive actinic keratoses on the face and scalp.12 Some 
limitations with the use of this laser are pain during the 
procedure and the potential for pigmentary changes. As an 
alternative, Wollina et al studied the erbium:YAG laser to 
treat actinic keratoses.13 The erbium:YAG laser is 10 times 
more selective of water than the carbon dioxide laser, which 
results in less thermal damage and is generally considered 
less painful. The authors treated 29 patients and found a 
complete response in 89.7% of the patients studied with no 
residual actinic keratoses discovered in the treatment area at 
a follow-up examination at 3 months. These lasers are better 
suited for larger treatment areas instead of isolated lesions 
due to prolonged healing times.
5-Fluorouracil
Topical 5-fluorouracil is a pyrimidine analog which has been 
used in the treatment of actinic keratoses for more than 50 
years since it was reported that intravenous fluorouracil led to 
resolution of numerous actinic keratoses.14 The   mechanism of 
action of fluorouracil involves its   ability to interfere with the Clinical, Cosmetic and Investigational Dermatology 2010:3 submit your manuscript | www.dovepress.com
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synthesis of nucleic acids through its metabolite, 5-fluorode-
oxyuridylic acid, which inhibits thymidylate   synthase.15 This 
inhibition is significant as thymidylate synthase catalyzes 
conversion of deoxyuridine 5-monophosphate to the DNA 
compound thymidine 5-monophosphate.16 By interfering 
with DNA synthesis, 5-flourouracil clears actinic keratoses as 
these lesions have neoplastic keratinocytes that have a higher 
rate of DNA synthesis than normal skin.15 Another proposed 
mechanism of action involves the incorporation of fluoroura-
cil into RNA, which interferes with RNA synthesis.16
There are numerous methods of utilizing 5-fluorouracil 
in the treatment of actinic keratoses. The most traditional 
method is continuous use once to twice daily over a period 
of 2–3 weeks. This method is quite effective with a   clearance 
rate of up to 75%.17 A major limitation of using 5-fluorouracil 
without breaks is complaints of erythema, pruritus, and pain. 
Systemic toxicity is rare and generally limited to patients with 
a deficiency of dihydropyrimidine dehydrogenase, which is 
a key enzyme that degrades up to 90% of   fluorouracil.18 The 
troublesome local adverse effects often lead to premature 
discontinuation of the product or noncompliance which 
effects efficacy of clearance. The resulting noncompliance 
stresses the importance of   physician education at the time 
of prescribing the product, either through verbal explanation 
or written handouts for the patient to review and decide if 
the treatment is appropriate for their lifestyle. As a result of 
the side-effect profile and consequent poor compliance, a 
study by Pearlman et al suggested a pulse-dosing   regimen of 
1–2 days per week over 6–8 weeks to decrease the adverse 
effects associated with 5-fluorouracil.19 Although there 
were less adverse effects, this treatment paradigm led to 
decreased efficacy as a direct correlation was found between 
the total weekly dosage and effectiveness in eradicating 
actinic keratoses.20 These findings were echoed by Jury et al 
who performed a randomized trial comparing 20 patients 
receiving either 5% 5-fluorouracil twice a day for 3 weeks 
versus 5% 5-  fluorouracil twice daily for just 1 day a week 
over 12 weeks.21 The authors found a statistically significant 
difference with improved efficacy in eradicating actinic 
keratoses with the group using 5% 5-fluorouracil twice a 
day for 3 weeks and concluded that although inflamma-
tion accounts for many of the adverse effects encountered 
by patients, it is likely necessary for improved treatment 
outcomes. Another approach to minimize the side-effect 
profile of 5-fluorouracil is through the use of a microsponge 
delivery system. This novel   delivery system consists of 
porous microspheres that enable the gradual delivery of 
5-fluorouracil on the epidermis and thereby minimize some 
of the local adverse effects.22
An attempt to elucidate the correct strength of 5-  fluorouracil 
to see the best way to ensure efficacy while minimizing 
adverse effects has been studied by several authors. Simmonds 
et al performed a split-face, double blind investigator study 
with 16 patients applying 1% 5-fluorouracil cream to one side 
of their face and 5% cream to the other side of the face.23 
The authors found there was no difference in efficacy 
between the two concentrations with less adverse effects noted 
with the lower concentration. Based on this work, Loven et al 
studied the tolerability and efficacy of a 0.5% 5-fluourouracil 
cream compared with 5% 5-fluorouracil cream in a similar 
split-face study.24 Subjects in the study applied the 0.5% cream 
once a day and the 5% concentration twice a day for 4 weeks 
or to the point where treatment became intolerable. Although 
the 0.5% cream was applied only once a day, there was no 
statistically significant difference in reduction of actinic kera-
toses between the two groups, with a higher patient preference 
towards the 0.5% 5-fluorouracil concentration due to the 
once daily application and more favorable adverse-effect 
profile with less erythema and pruritus being noted. As there 
were only 21 patients enrolled in the Loven study, the efficacy 
of 0.5% 5-fluorouracil cream was confirmed by Weiss et al 
in a larger study of 177 patients.25 The authors performed a 
randomized, placebo-controlled, double-blind, multicenter 
study in which patients were divided into two groups and 
evaluated at 1, 2, or 4 weeks from the time of initiation of 
treatment. Statistically significant differences in reduction of 
actinic keratoses were seen with the once daily application 
of 0.5% 5-fluouracil cream compared with placebo at each 
evaluation time, with a 78.5% reduction from baseline at 
week 1, a 83.6% reduction at week 2, and a 88.7% reduction 
at week 4. Interestingly, patients completing 4 weeks of 
therapy noted only a slight increase in erythema and irritation 
after week 2. Subjects reported a cessation of all adverse 
effects within 17 days of completing therapy. Given the once-
daily application and less side effects compared with other 
concentrations, the use of 0.5% 5-flurouracil cream appears 
to be the most cost-effective choice of the three concentrations 
for physicians to use in their practices.
Diclofenac sodium
Diclofenac sodium is a nonsteroidal anti-inflammatory 
agent whose mechanism of action in the treatment of actinic 
  keratoses involves its ability to inhibit cyclooxygenase 
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keratoses and catalyzes the synthesis of prostaglandins. The 
resulting inhibition of COX-2 decreases the byproducts of 
arachidonic acid and thereby hinders tumor angiogenesis.27
An initial study by Rivers et al assessed the efficacy 
of diclofenac sodium in hyaluronic acid in a study of 
27 patients.28 At 1 month following the initial use of the 
medication, a complete response was found in 81% of the 
patients. The most common adverse effect was that of an 
irritant contact dermatitis at the site of treatment. As a result 
of these initial findings, a larger randomized, double-blind 
placebo controlled study was undertaken by Wolf et al.29 
In this study, 96 patients with at least five discrete actinic 
keratoses located on the face, scalp, arms, or hands were 
treated with either the inactive gel vehicle, hyaluronic acid, or 
diclofenac sodium in hyaluronic acid twice daily for 90 days. 
Each patient was evaluated 30 days after the completion of 
therapy, with 79% of patients reporting complete or partial 
clearance of actinic keratoses. Another study attempted to 
determine the appropriate length of time patients need to 
be treated with diclofenac sodium in hyaluronic acid.30 One 
hundred and ninety-six patients were studied in both 30- and 
60-day application periods. The investigators found a statisti-
cally significant better response with 60 days of treatment 
compared with 30 days.
A recent paper outlined a new way to consider the treat-
ment of actinic keratoses by using diclofenac sodium in 
hyaluronic acid in the treatment of actinic keratoses after 
cryosurgery.31 The goal of the study was to see if sequential 
therapy led to a higher overall cure rate than that seen with 
each individual therapy. In this study, 521 patients were 
randomized into two treatment arms: treatment with cryo-
surgery alone and cryosurgery followed by the application 
of diclofenac sodium 3% gel in 2.5% hyaluronic acid for 
90 days. Lesion counts were obtained in target areas such as 
the forehead, scalp, and hands at baseline, and 45, 75, 105, 
and 135 days after cryosurgery. At day 135, 100% clearance 
in the target area was achieved in 64% of the subjects in the 
cryosurgery followed by diclofenac sodium 3% gel in 2.5% 
hyaluronic acid arm compared with 32% in subjects treated 
with cryosurgery alone. The average percent reduction in all 
target lesions over time for those subjects in the cryosurgery 
followed by diclofenac sodium 3% gel in 2.5% hyaluronic 
acid started with 69% at treatment day 45 reaching an 89% 
target lesion reduction at day 135, with the mean number of 
target lesions being reduced from 8.9 at baseline to 1.1 at the 
conclusion of the study. The authors concluded that a reason 
for the synergistic effect was that both clinically apparent 
actinic keratoses as well as subclinical lesions were treated 
by combining treatment modalities.
Imiquimod
Imiquimod 5% cream was initially approved by the US 
Food and Drug Administration in 1997 for the treatment of 
external genital and perianal human papillomavirus (HPV) 
infections. It subsequently gained approval for the use of 
nonhyperkeratotic, nonhypertrophic actinic keratoses in 
2004, and subsequently superficial basal cell carcinomas 
in immunocompetent adults. The finding of HPV DNA in 
actinic keratoses is a reason why imiquimod is effective in 
treating both external genital and perianal warts as well as 
actinic keratoses.32 Iftner et al found HPV DNA in 60.4% of 
actinic keratoses versus 4.7% in controls.32
Imiquimod is a member of the imidazoquinoline fam-
ily, and there are several proposed mechanisms of action 
to explain the efficacy towards actinic keratoses. One such 
mechanism of action involves the ability to activate innate 
immune cells through the Toll-like receptor 7 pathway to 
increase cytokine production.33 The Toll-like receptor 7 is 
one of 11 Toll-like receptors that allow the innate immune 
system to detect foreign pathogens.34 Once the foreign 
pathogen is detected, Toll-like receptor 7 causes NF-κB 
to dissociate from its inhibitor and diffuse into the nucleus 
where it aids in gene transcription of tumor necrosis factor 
alpha, interleukins 1, 6, 8, and 12, and interferons alpha 
and gamma.35 These cytokines increase the cell-mediated 
type 1 helper T cell response and consequent destruction of 
actinic keratoses. Additionally, imiquimod directly activates 
cytotoxic T lymphocytes and natural killer cells through 
activation of antigen-presenting Langerhans cells.35 Lastly, 
imiquimod stimulates the proliferation of B cells and upregu-
lates the receptors required in the p53 apoptotic pathway.36 
In contrast to 5-fluourouracil, which has to penetrate each 
individual actinic keratosis to be effective, imiquimod is not 
a cytotoxic agent, and the immune response elicited from 
this medication appears to extend deeper than the level of 
the medication’s penetration.6
An initial study by Stockfleth et al investigated the use of a 
once daily application of 5% imiquimod cream 3 times a week 
for 6–8 weeks on six patients with actinic keratoses located 
on the scalp.37 The authors found both clinical and histologic 
evidence of clearing of all of the actinic keratoses during the 
follow-up period which ranged from 3–12 months. Based upon 
these initial findings, Korman et al reviewed two larger Phase III 
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multicenter studies with a total of 492 patients.38 In the study, 
patients applied 5% imiquimod or vehicle cream once daily, 
three times per week for 16 weeks, to affected areas on the 
face or balding scalp and were evaluated 8 weeks after the last 
treatment. The median percentage reduction of baseline lesions 
was 86.6% for the imiquimod-treated group compared with 
14.3% for the vehicle-treated group. Complete clearance rates 
of imiquimod-treated patients was statistically significantly 
higher than the vehicle-treated group, with a 48.3% rate noted 
in the imiquimod treatment arm. An interesting observation 
noted by Korman et al was an initial increase in the number 
of actinic keratoses when patients first used imiquimod. This 
occurrence has been hypothesized to be the result of subclini-
cal lesions being uncovered as opposed to new lesions being 
created.38 Adverse effects occurred in 73% of the subjects 
reviewed by Korman et al and commonly included erythema, 
scabbing, and flaking. The authors found that the patients 
which experienced a greater degree of these local adverse 
effects correlated with a greater chance of complete and partial 
clearance rates. In an attempt to reduce these adverse effects 
while still maintaining promising treatment results, two recent 
studies compared the efficacy and tolerability of imiquimod 
3.75% cream and imiquimod 2.5% cream to investigate these 
lower doses of imiquimod.
The first study by Swanson et al was a randomized, 
placebo controlled trial of 479 patients placed into three 
groups: placebo, imiquimod 2.5% cream, and imiquimod 
3.75% cream.39 Each of these groups was treated cyclically 
for 2 weeks followed by a 2-week rest period and concluded 
with an additional 2-week treatment period. The patients 
then returned 8 weeks after completing their last 2-week 
cycle to determine the percentage of lesion reduction from 
baseline. The median reductions in lesion count were 25% 
for placebo, 71.8% for imiquimod 2.5% cream, and 81.8% 
for imiquimod 3.75%. Although these clearance rates were 
somewhat less than those found with imiquimod 5% cream, 
the study with these lower dosages of imiquimod treated 
a larger treatment area with more baseline lesions. With a 
greater area of treatment as well as more initial lesions, it is 
not surprising that the median reduction in lesion count was 
lower in the study of imiquimod 3.75% and 2.5%. Local 
skin reactions such as erythema, scabbing, pruritus, and ero-
sions were most commonly reported in the treatment groups. 
Although these treatment-related adverse effects were 19.4% 
in the treatment group versus 2.5% in the placebo group, the 
placebo group actually had a slightly higher rate of study 
discontinuation at 1.9% versus 1.2%. The second study by 
Hanke et al confirmed the aforementioned results, but the 
patients were treated an additional week with two 3-week 
cycles.40 The median reductions in lesion count were 23.6% 
for placebo, 66.7% for imiquimod 2.5% cream, and 80.0% 
for imiquimod 3.75%. Given the comparable efficacy to the 
study by Swanson et al, patient compliance will be improved 
with the shorter treatment regimen of 2-week cycles.
Ingenol mebutate
Ingenol mebutate (ingenol-3-angelate, formerly PEP005) 
represents a new treatment for actinic keratoses. This novel 
agent is purified and extracted from the sap of the plant 
Euphorbia peplus and whose mechanism of action involves 
its ability to cause cellular necrosis through disruption of the 
plasma membrane and mitochondria.41 Additionally, ingenol 
mebutate stimulates neutrophil-mediated and antibody-
dependent cellular cytotoxicity to eradicate any residual 
diseased cells.42
An initial study by Siller et al investigated the safety and 
efficacy of ingenol mebutate in a randomized, double-blind, 
vehicle-controlled, multicenter study of 58 patients.43 Patients 
received two total daily applications of either ingenol mebu-
tate gel 0.0025%, 0.01%, or 0.05%, or placebo vehicle gel. 
The authors found the greatest efficacy with ingenol mebutate 
gel 0.05%, with a complete clinical clearance rate of 71%. 
The treatment was well tolerated with only local adverse 
effects of erythema, flaking, and crusting being reported. 
The results of this study were confirmed by Anderson et al 
with a larger sample size of 222 patients.44 In this study, 
patients were randomized to receive either vehicle gel for 
3 days, ingenol mebutate gel 0.025% for 3 days, or ingenol 
mebutate 0.05% for 2 or 3 days, with an 8-week follow-up 
period. The authors found the clinical responses to be dose 
dependent for all measures of efficacy with the most statisti-
cally significant rates of clearance occurring with the group 
receiving ingenol mebutate 0.05% for 3 days. This group had 
a partial clearance rate of at least 75% resolution of baseline 
lesions in 75.4% of patients and a complete clearance rate of 
54.4%. An advantage of this treatment is the short 2–3 day 
course of therapy, which will help to improve compliance in 
patients who are not adherent to some of the aforementioned 
longer treatment regimens.
Photodynamic therapy
An emerging treatment for actinic keratoses is the use 
of   topical 5-aminolevulinic acid (5-ALA) photodynamic 
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penetrates the stratum corneum and is absorbed by actinic 
keratoses, pilosebaceous units, and nonmelanoma skin 
cancer cells.45 Once the prodrug 5-ALA is absorbed, it is 
converted into its active drug, protoporphyrin IX which can 
be detected in the epidermis four hours after application.46 
The active drug can then peakly absorb two different light 
wavelength sources: blue light (400–450 nm), known as the 
Soret band, and red light (640 nm). Once activated, reactive 
oxygen intermediates such as singlet oxygen are created 
that result in apoptosis and vascular endothelial damage.47 
The use of 5-ALA photodynamic therapy was approved 
by the US Food and Drug Administration for the treatment 
of nonhyperkeratotic actinic keratoses after a 14–18 hour 
incubation period followed by exposure to blue light for 
16 minutes and 40 seconds.45
An initial study by Jeffes et al used a single treatment of 
30% 5-ALA with activation from a 630 nm argon pumped 
dye laser for actinic keratoses on the face, scalp, trunk, and 
extremities.48 The patients were evaluated 2 months follow-
ing treatment with a 91% complete clearance rate on the 
face and scalp compared with a 45% rate of clearance on the 
trunk and extremities. The authors concluded that the treat-
ment was more effective on thinner lesions and less likely to 
improve thick, hyperkeratotic actinic keratoses. The superior 
clearance rate for actinic keratoses on the face and scalp 
was confirmed by a randomized, placebo-controlled study 
of 243 patients by Piacquadio et al who evaluated 5-ALA 
photodynamic therapy versus placebo in the treatment of 
multiple actinic keratoses on the face and scalp.49 The patients 
in both groups were evaluated following therapy at 24 hours, 
1 week, 4 weeks, 8 weeks, and 12 weeks. At 8 weeks, 77% 
of patients receiving 5-ALA photodynamic therapy experi-
enced 75% or more clearing of treated lesions versus 18% 
for placebo. In the study, the patients tolerated the 5-ALA 
photodynamic therapy well with the burning sensation dur-
ing light treatment markedly decreasing within 24 hours of 
therapy and complaints of erythema and edema at the treated 
sites improving within 1–4 weeks after therapy.
5-ALA methylester is another photosensitizer that has 
been used in the treatment of actinic keratoses. It had been 
proposed that 5-ALA methylester may result in greater 
efficacy due to superior lipophilicity allowing enhanced 
penetration into atypical cells in comparison with 5-ALA. 
A study by Moloney and Collins investigated this question 
by comparing the two photosensitizers in 16 patients with 
extensive scalp actinic keratoses.50 In the study, each pho-
tosensitizer was applied to either the left or right side of the 
scalp, thereby allowing for a direct comparison of the same 
patient. The results of this double-blind, split-scalp study 
found a similar reduction in the number of actinic keratoses 
with no statistically significant difference found in the effi-
cacy between the two photosensitizers. However, patients 
reported more pain, both during treatment and post-treatment, 
with 5-ALA in comparison with 5-ALA methylester. Another 
consideration in deciding between these two photosensitizers 
is cost, as 5-ALA methylester is more expensive than 5-ALA 
in many countries.
A study by Kurwa et al examined the effectiveness of 
topical 5-fluorouracil compared with 5-ALA photodynamic 
therapy.51 In the study, 14 patients’ right and left hands with 
actinic keratoses were randomized to receive either a 3-week 
course of 5-fluorouracil or 5-ALA photodynamic therapy. 
Lesion counts and tolerability were compared at weeks 1, 4, 
and 24 after initiation of treatment. The results of the study 
showed equal efficacy among the two treatments, without any 
statistically significant difference in clearance rates of actinic 
keratoses. However, 5-ALA photodynamic therapy did elicit 
a faster response and is a viable alternative for patients who 
have contact sensitivity to 5-fluorouracil or are noncompliant 
with the 5-fluorouracil treatment regimen.
Conclusion
Actinic keratoses are a common problem that physicians face 
on a daily basis. With the increased frequency of sun damage 
coupled with the aging of the population, the incidence of 
actinic keratoses will continue to rise. It is important to under-
stand the various treatment options available to tailor therapy 
to each patient’s needs. The number of actinic keratoses, the 
patient’s tolerance to known side effects, and the amount of 
background photodamage in the treatment area are among 
factors that physicians need to consider. The treatments 
reviewed emphasize the importance to treat both individual 
actinic keratoses that are apparent as well as subclinical 
lesions that will later turn into precancerous lesions. With 
the well known transition of actinic keratoses to cancerous 
lesions, new therapies as well as the use of treatments in 
combination will become more prevalent.
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